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Accumulation of low-density lipoproteins (LDL) and lipids in the subendothelial matrix and macrophages is 
crucial in the pathogenesis of atherosclerosis.1 Conversely, 
removal of cholesterol from the subendothelial space by cho-
lesterol efflux and subsequent reverse cholesterol transport 
have been postulated to confer protection against atheroscle-
rosis.2 To reach the subendothelial space, both LDL and high-
density lipoprotein (HDL) have to cross the intact endothelial 
barrier. It is yet controversial whether transendothelial HDL 
transport is mediated by specific mechanisms or the result of 
passive filtration.3,4 Our laboratory previously showed that aor-
tic endothelial cells are able to specifically bind, internalize, 
and transport HDL in a saturable and temperature-dependent 
manner via a nonclassical endocytic route involving dynamin 
and cytosketal networks.5,6 We also demonstrated that trans-
cytosis of mature HDL is regulated by ATP-binding cassette 
transporter ABCG1, scavenger receptor BI (SR-BI), and 
endothelial lipase, as well as the ectopic-β ATPase/purinergic 
receptor axis.6–8 Other laboratories reported that endothelial 
cells internalize LDL by at least 2 pathways3: The classical 
one leads to lysosomal degradation and involves clathrin-
coated pits and the LDL receptor.9,10 The other nondegrading 
pathway allows the transendothelial transport of LDL and 
involves caveolae,11 SR-BI,12 and activin-like kinase 1.13
Genome-wide RNA interference studies have shown 
that both clathrin- and caveolin-dependent endocytosis are 
regulated by kinases.14 The kinases regulating the endo-
cytosis of lipoproteins especially by endothelial cells are 
unknown. To identify such signaling cascades regulating the 
uptake of LDL and HDL, we performed a microscopy-based 
high-content screening on human aortic endothelial cells 
(HAECs) using a kinase inhibitor drug library. Starting with 
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Objective—Low- and high-density lipoproteins (LDL and HDL) must pass the endothelial layer to exert pro- and 
antiatherogenic activities, respectively, within the vascular wall. However, the rate-limiting factors that mediate 
transendothelial transport of lipoproteins are yet little known. Therefore, we performed a high-throughput screen with 
kinase drug inhibitors to identify modulators of transendothelial LDL and HDL transport.
Approach and Results—Microscopy-based high-content screening was performed by incubating human aortic endothelial 
cells with 141 kinase-inhibiting drugs and fluorescent-labeled LDL or HDL. Inhibitors of vascular endothelial growth 
factor (VEGF) receptors (VEGFR) significantly decreased the uptake of HDL but not LDL. Silencing of VEGF receptor 
2 significantly decreased cellular binding, association, and transendothelial transport of 125I-HDL but not 125I-LDL. RNA 
interference with VEGF receptor 1 or VEGF receptor 3 had no effect. Binding, uptake, and transport of HDL but not 
LDL were strongly reduced in the absence of VEGF-A from the cell culture medium and were restored by the addition 
of VEGF-A. The restoring effect of VEGF-A on endothelial binding, uptake, and transport of HDL was abrogated by 
pharmacological inhibition of phosphatidyl-inositol 3 kinase/protein kinase B or p38 mitogen-activated protein kinase, 
as well as silencing of scavenger receptor BI. Moreover, the presence of VEGF-A was found to be a prerequisite for the 
localization of scavenger receptor BI in the plasma membrane of endothelial cells.
Conclusions—The identification of VEGF as a regulatory factor of transendothelial transport of HDL but not LDL supports the 
concept that the endothelium is a specific and, hence, druggable barrier for the entry of lipoproteins into the vascular wall.
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this unbiased strategy, we found evidence for an important 
regulatory role of vascular endothelial growth factor (VEGF) 
and its cognate VEGF receptor-2 (VEGFR2), as well as its 
downstream signaling kinases in regulating uptake of HDL 
but not LDL by endothelial cells. The validation of this dis-
covery did not only confirm the findings of the screen but 
also unraveled a regulatory role of VEGF-A on the subcel-
lular trafficking of SR-BI.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
Screening of Kinase Inhibitors
After culture for 72 hours in 384 well plates at a density of 
1000 cells per well, HAECs were treated with 141 kinase-
inhibiting drugs for 1 hour at 7 different dilutions spanning 4 
orders of magnitude. Thereafter, cells were incubated with flu-
orescent-labeled Atto 594-LDL or Atto 594-HDL for another 
hour. After washing, fixation, and nuclei staining, 9 images 
per well were acquired using a molecular devices wide-field 
microscope. The microscope-generated images were pro-
cessed by Cell profiler to segment nuclei and RFP (red flu-
orescent protein) foci intensity (vesicles) per cell. For each 
compound interaction, the amount of downregulation was cal-
culated relative to a control reaction in the presence of vehicle 
(dimethyl sulfoxide). The analysis of the dose-response data 
for LDL and HDL uptake by the use of the Hill model (see 
methods) identified 2 and 9 drugs, respectively, with a Hill 
coefficient of 4, which, therefore, were suspicious of toxicity 
and, hence, excluded from further analysis (Tables I and II in 
the online-only Data Supplement). The drugs were preclassi-
fied as active based on their ability to fit the Hill logistic model 
only when the RFP foci signal dropped >50%. Finally, using 
Fisher exact test, we statistically evaluated the probability 
of finding drugs targeting a kinase that actively decrease the 
uptake of fluorescent LDL or HDL in the presence of maximal 
concentration versus nontargeting drugs. After correction of P 
values for multiple statistical testing, VEGFR emerged as the 
only target whose inhibition significantly interfered with the 
HDL uptake by HAECs. However, this analysis did not reveal 
any target whose inhibition led to a significant and consistent 
decrease in LDL uptake (Table).
VEGFR2 Regulates Endothelial Binding, 
Association, and Transport of HDL but Not LDL
We first confirmed the regulatory role of VEGFR in the uptake 
of HDL by HAECs and to identify the relevant VEGF receptor 
by a knockdown strategy. HAECs expressed all 3 VEGF recep-
tors: VEGFR1, VEGFR2, and VEGFR3 as analyzed by quan-
titative reverse transcriptase polymerase chain reaction (Figure 
IA in the online-only Data Supplement). To test which VEGF 
receptor was involved in HDL uptake, each of the 3 VEGF 
receptors was targeted using RNA interference. Although 
knockdown was efficient for each VEGFR on the mRNA level 
(Figure IB in the online-only Data Supplement) and protein 
level (Figure IC in the online-only Data Supplement), only 
the silencing of VEGFR2 decreased the cellular uptake of flu-
orescent-labeled Atto594-HDL, whereas silencing VEGFR1 
and VEGFR3 showed no effect (left lane of Figure II in the 
online-only Data Supplement). These findings were confirmed 
using radioiodinated HDL, where silencing of VEGFR2 sig-
nificantly reduced the specific 4°C binding of 125I-HDL to 
endothelial cells by 60% (Figure 1A), the specific 37°C cellu-
lar association by 80% (Figure 1B), and the specific transendo-
thelial transport of 125I-HDL from apical to basal compartment 
at 37°C by 60% (Figure 1C). However, neither cellular uptake 
of fluorescent-labeled Atto488-LDL (right lane of Figure II in 
the online-only Data Supplement) nor specific cellular bind-
ing, association, and transendothelial transport of 125I-LDL 
were affected by silencing of any VEGF receptor (Figure 1D 
through 1F). Taken together, these results indicate a specific 
effect of VEGFR2 on endothelial binding and uptake, as well 
as transendothelial transport of HDL but not LDL.
VEGF-A Regulates Endothelial Binding, 
Association, and Transport of HDL but Not LDL
Binding of VEGF-A to its receptor VEGFR2 induces confor-
mational changes and receptor dimerization, which in turn 
triggers kinase activation and autophosphorylation of tyrosine 
residues.15 To investigate whether VEGF-A regulates transen-
dothelial transport of HDL, we cultured endothelial cells either 
in the VEGF-A-containing medium A or in the VEGF-A-free 
medium B. The presence or absence of VEGF in the medium 
had no effect on the proliferation of HAECs (Figure IIIA in 
the online-only Data Supplement). On Western blot analysis, 
we found that HAECs cultured in VEGF-free medium for 72 
hours lose phosphorylation of Tyr residues 1054 and 1059 
in the major tyrosine kinase catalytic domain of VEGFR2 
(Figure IIIB in the online-only Data Supplement).
As shown in the left panel of Figure IV in the online-
only Data Supplement, cells cultured in VEGF-free medium 
for 72 hours decreased the cellular uptake of Atto594-HDL 
compared with cells cultured in VEGF-containing medium 
(control). Interestingly, pretreatment of cells cultured in 
medium B supplemented with 25 ng/mL VEGF-A for 1 
hour showed a significant increase in the uptake of Atto594-
HDL (lowest figure in the left lane). Confirming these 
microscopic findings, pretreatment of cells for 1 hour with 
VEGF-A significantly increased 4°C cellular binding of 125I-
HDL (Figure 2A) and 37°C cellular association of 125I-HDL 
(Figure 2B), as well as apical to basolateral transendothelial 
Nonstandard Abbreviations and Acronyms
Akt protein kinase B
HAEC human aortic endothelial cells
HDL high-density lipoprotein
LDL low-density lipoprotein
MEK mitogen-activated protein kinase kinase
p38 MAPK p38 mitogen-activated protein kinase
PI3K phosphatidylinositol-4,5-bisphosphate 3-kinase
SR-BI scavenger receptor class B type I
VEGF vascular endothelial growth factor
VEGFR vascular endothelial growth factor receptor
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transport of 125I-HDL (Figure 2C) compared with cells cul-
tured in VEGF-free medium.
By contrast, cells cultured in VEGF-free medium for 72 
hours did not show any decrease in the uptake of Atto488-
LDL compared with the control condition (right lane of Figure 
IV in the online-only Data Supplement). Likewise, presence, 
absence, or supplementation of VEGF-A had no effect on 
the cellular binding, association, and transport of 125I-LDL 
(Figure 2D, 2E, and 2F).
Taken together, these results indicate that VEGF-mediated 
VEGFR2 receptor activation is required for endothelial bind-
ing and uptake, as well as transendothelial transport of HDL 
but not LDL.
VEGF-A Regulates Endothelial Binding and 
Association of HDL Through p38 Mitogen-
Activated Protein Kinase and Phosphatidyl-
inositol 3 Kinase/Protein Kinase B
We determined whether the pharmacological inhibition 
of the downstream kinases of VEGF signaling, namely 
phosphatidyl-inositol 3 kinase (PI3K), p38 mitogen activated 
protein kinase (p38 MAPK), and mitogen-activated protein 
kinase kinase (MEK), interfere with endothelial binding and 
association of HDL. Cells were pretreated with indicated 
drugs for 30 minutes followed by pretreatment with 25 ng/
mL of VEGF-A for 1 hour at 37°C. Western blot analysis 
revealed that residue Ser473 of protein kinase B (Akt; the 
downstream kinase targeted by PI3K), residues Thr180 and 
Tyr182 of p38 MAPK, and residues Thr202, Tyr204, Thr185, 
and Tyr187 of p44/42 MAPK (ERK1/2 [extracellular signal-
regulated kinase], which is a common kinase target of MEK1 
and MEK2) were phosphorylated in the presence but not in 
the absence of VEGF (Figure IIIB in the online-only Data 
Supplement). Treatment with either the PI3K inhibitor wort-
mannin or the Akt inhibitor MK 2206 or the p38 MAPK 
inhibitor PD169316 decreased the cellular binding and asso-
ciation of 125I-HDL. These inhibitory effects were not over-
come by pretreatment with VEGF-A. Also the dual MEK1 
and MEK2 inhibitor U0126 significantly decreased the cellu-
lar binding and association of 125I-HDL. However, by contrast 
Table.  Fisher Exact Test Analysis of Binary Activity Signal for Uptake of LDL and HDL
Target
LDL HDL
n m n′ m′ P Value n m n′ m′ P Value
ABL 1 5 26 113 0.71653 2 4 51 88 0.714
ALK 1 3 26 115 0.56562 1 3 52 89 0.842
c-Kit 1 6 26 112 0.77159 3 4 50 88 0.505
c-Met 4 7 23 111 0.12361 5 6 48 86 0.369
EGFR 3 11 24 107 0.50494 8 6 45 86 0.084
FGFR 2 4 25 114 0.31014 3 3 50 89 0.383
FLT-3 0 1 27 117 1 0 1 53 91 1
HER2 2 5 25 113 0.38616 4 3 49 89 0.221
IGF-1R 1 0 26 118 0.18621 1 0 52 92 0.366
VEGFR 9 22 18 96 0.08137 18 13 35 79 0.005*
Aurora 5 10 22 108 0.11871 7 8 46 84 0.278
CDK 2 6 25 112 0.45878 1 7 52 85 0.977
CHK 0 1 27 117 1 0 1 53 91 1
GSK-3 0 3 27 115 1 0 3 53 89 1
JNK 0 1 27 117 1 0 1 53 91 1
JAK/STAT 1 3 26 115 0.56562 0 4 53 88 1
MEK 1 10 26 108 0.90542 4 7 49 85 0.623
mTOR 0 10 27 108 1 1 9 52 83 0.991
PI3K/AKT 1 17 26 101 0.98121 2 16 51 76 0.998
p38 MAPK 2 5 25 113 0.38616 2 5 51 87 0.798
For each target, Fisher exact test analysis was used to calculate the probability to get more active drugs (m) and less active drugs (n) for a given target and at the same 
time less active drugs (m′) and more active (n′) drugs for nontargets. The drugs were preclassified as active based on their ability to fit the Hill logistic model only when the 
RFP (red fluorescent protein) foci signal dropped >50%. ABL indicates Abelson murine leukemia viral oncogene homolog 1; AKT, protein kinase B; ALK, anaplastic lymphoma 
kinase; Aurora, Aurora kinase; c-Kit, tyrosine-protein kinase kit or CD117; c-Met, tyrosine-protein kinase met; CDK, cyclin-dependent kinase; CHK, check-point kinase; 
EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; FLT-3, fms-like tyrosine kinase 3; GSK-3, glycogen synthase kinase-3; HDL, high-density 
lipoprotein; HER2, receptor tyrosine-protein kinase erbB-2 or CD340; IGF-1R, insulin growth factor receptor; JAK/STAT, Janus kinase and signal transducer and activator of 
transcription proteins; JNK, c-Jun N-terminal kinase; LDL, low-density lipoprotein; MEK, mitogen-activated protein kinase kinase; mTOR, mammalian target of rapamycin; 
p38 MAPK, p38 mitogen-activated protein kinase; PI3K/AKT, phosphotidyl-inositol 3 kinase/protein kinase B; and VEGFR, vascular endothelial growth factor receptor.
Inhibition of targets with *P≤0.01 are interpreted to be more likely than the inhibition of all other targets to decrease the uptake of LDL or HDL. The data were obtained 
from 2 replicate experiments.
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to wortmannin, MK 2206, and PD169316, pretreatment with 
VEGF-A restored the inhibitory effect of U0126 on endothe-
lial binding and association of HDL (Figure 3A and 3B). The 
effects of pharmacological inhibitors were confirmed by using 
RNA interference of Akt, p38 MAPK, and MEK1/MEK2. 
The knockdown was found efficient for each kinase on the 
protein level (Figure V in the online-only Data Supplement). 
Like the pharmacological inhibitors, silencing of either 
Akt or p38 MAPK or MEK1/2 decreased the cellular bind-
ing and association of 125I-HDL. Also on RNA interference, 
VEGF-A treatment restored the cellular binding and associa-
tion of 125I-HDL by endothelial cells lacking MEK1/2 but not 
by endothelial cells lacking Akt or p38 MAPK. (Figure VI 
in the online-only Data Supplement). Taken together, these 
results show that VEGF-induced binding and association of 
HDL depends on the activation of PI3K/Akt and p38 MAPK 
but is independent of the MEK/ERK pathway. Interestingly, 
endothelial binding or cell association of 125I-LDL was not 
affected by silencing of Akt but significantly decreased by 
silencing of p38 MAPK and MEK (Figure VII in the online-
only Data Supplement).
VEGF-A Regulates Binding, Association, 
and Transport of HDL via SR-BI
We have previously demonstrated that SR-BI, ABCG1, and 
endothelial lipase regulate binding and transendothelial 
transport of HDL. Because of the fast effects of VEGF-A 
on cellular binding, association, and transport of 125I-HDL, 
we hypothesized that VEGF-A regulates the availability of 
one of these HDL interacting proteins on the cell surface in 
HAECs. To test this hypothesis, we performed a cell surface 
biotinylation experiment. HAECs cultured in the VEGF-
free cell culture medium did not show any SR-BI on the cell 
surface. Pretreatment with VEGF-A restored the expression 
of cell surface SR-BI. By contrast, the presence or absence 
of VEGF-A had no effect on the cell surface expression of 
LDL receptor, ABCG1, or endothelial lipase (Figure 4). To 
determine whether VEGF-A regulated HDL transendothelial 
transport through SR-BI, we silenced SR-BI using RNA inter-
ference. The knockdown was efficient at the mRNA (Figure 
VIIIA in the online-only Data Supplement) and protein levels 
(Figure VIIIB in the online-only Data Supplement). Silencing 
SR-BI alone significantly decreased 125I-HDL cellular binding 
Figure 1. Vascular endothelial growth factor receptor 2 (VEGFR2) mediates binding, association, and transendothelial transport of high-
density lipoprotein (HDL) but not low-density lipoprotein (LDL) in human aortic endothelial cells (HAECs). HAECs were transfected with a 
specific siRNA against VEGFR2 or with nonsilencing control siRNA (NS control), and assays were performed 72 hours after transfection. 
To study cellular binding, association, and transport, transfected endothelial cells (ECs) were incubated with 10 μg/mL of 125I-HDL or 125I-
LDL for 1 hour in the absence (total) or in the presence of 40-fold excess of unlabeled HDL and LDL, respectively, to record unspecific 
interactions. Specific binding, association, and transport were calculated by subtracting unspecific values from total values. A, Specific 
binding was measured by incubating cells with 125I-HDL (A) or 125I-LDL (D) at 4°C. To measure specific cell association, cells were incu-
bated with 125I-HDL (B) or 125I-LDL (E) at 37°C. For the measurement of transport, HAECs were cultured on inserts. The transport of 125I-
HDL (C) and 125I-LDL (F) from the apical to basolateral compartment was measured at 37°C. The results are represented as means±SEM 
of 3 independent triplicate experiments (n=3). ***P≤0.001, **P≤0.01, *P≤0.05, and ns indicates not significant.
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and association by 50% to 55% and transport by 60%, respec-
tively. Pretreatment with VEGF-A for 1 hour did not restore 
the cellular binding, association, and transport of 125I-HDL 
inhibited by suppression of SR-BI (Figure 5A through 5C).
Discussion
We previously reported that bovine aortic endothelial cells 
bind, internalize, and transport HDL in a specific process 
dependent on SR-BI, ABCG1,6 endothelial lipase,7 and ecto-
pic β-ATPase.8 Here we show that HAECs also bind, internal-
ize, and transport HDL, as well as LDL. Using a high-content 
drug screening approach, we identified VEGF-A/VEGFR2 
signaling as a rate-limiting factor for the cell surface abun-
dance of SR-BI and, as a consequence, regulator of uptake 
and transport of HDL by HAECs. Interestingly, VEGF-A and 
VEGFR2 had no effect on endothelial binding, uptake, and 
transport of LDL.
VEGFs are important regulators of both vasculogenesis 
and angiogenesis in the adult.16 In mammals, the VEGF fam-
ily encompasses 5 different isoforms namely, VEGF-A, - 
B, -C, and –D, as well as placenta growth factor. These 
ligands bind to 3 VEGF receptors—VEGFR1, VEGFR2, 
and VEGFR3—in an overlapping pattern. VEGF-A, 
VEGF-B, and placenta growth factor bind to VEGFR117–19; 
VEGF-A binds to VEGFR220; VEGF-C and VEGF-D bind to 
VEGFR3.21,22 Among VEGF-A receptors, VEGFR1 has the 
highest affinity and acts as a negative regulator by seques-
tering VEGF-A from binding to VEGFR223; hence, VEGFR2 
is the key receptor mediating most of the cellular effects of 
VEGF-A in endothelial cells. In accordance with this, our 
results show that RNA interference with VEGFR2 but not 
with VEGFR1 decreases HDL uptake (Figure II in the online-
only Data Supplement). Our data show some analogy with 
those reported by Lim et al24 and Martel et al,25 who observed 
improved lymphatic function and transport of HDL after 
VEGF-C treatment in mice.
Binding of VEGF-A induces conformational changes and 
dimerization of VEGFR2, which in turn triggers kinase acti-
vation, tyrosine phosphorylation of the dimerized VEGFR2, 
and subsequent phosphorylation of SH2-containing intracel-
lular signaling proteins, including phospholipase C-γ1, Src 
family tyrosine kinases, and PI3K and Ras GTPase-activating 
protein residues of Ras-Raf-MEK-MAPK pathway.26–29 
VEGF was also shown to induce actin remodeling through 
activation of CDC42 and p38 MAPK.30 Both by pharma-
cological inhibition and RNA interference, we revealed the 
involvement of PI3K/Akt, p38 MAPK, and the Ras-Raf-
MEK pathway in binding and uptake of HDL (Figure 3; 
Figure 2. Effect of vascular endothelial growth factor (VEGF)-A on binding, association, and transendothelial transport of high-density 
lipoprotein (HDL) and low-density lipoprotein (LDL) in human aortic endothelial cells (HAECs). HAECs were cultured in medium contain-
ing VEGF-A (control) or lacking VEGF-A (no VEGF) for 72 hours. Cells were pretreated with 25 ng/mL of VEGF-A165 for 1 hour prior to the 
assays if indicated. Specific binding was measured by incubating cells with 125I-HDL (A) and 125I-LDL (D) at 4°C. Specific cell association 
was analyzed by incubating cells with 125I-HDL (B) and 125I-LDL (E) at 37°C. HAECs were cultured on inserts, and transport of 125I-HDL (C) 
and 125I-LDL (F) from the apical to basolateral compartment was measured at 37°C. The results are represented as mean±SEM of 3 inde-
pendent triplicate experiments (n=3). ***P≤0.001, **P≤0.01, *P≤0.05, and ns indicates not significant.
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Figure 3. Vascular endothelial growth factor (VEGF)-A regulates high-density lipoprotein (HDL) binding and association through phos-
phatidyl-inositol 3 kinase/protein kinase B (PI3K/Akt) and p38 mitogen-activated protein kinase (p38 MAPK). Human aortic endothelial 
cells (HAECs) were cultured in the presence or absence of VEGF-A for 72 hours. Cells were then treated with Wortmannin (200 nM), or 
MK2206 (1 μM), or U0126 (10 μM), or PD169316 (100 nM) for 30 min, followed by treatment with 25 ng/mL VEGF-A165 for 1 hour at 37°C 
if indicated. A, Specific binding was measured by incubating cells with 125I-HDL at 4°C. B, Specific cell association was analyzed by incu-
bating cells with 125I-HDL at 37°C. The results are represented as means±SEM of 3 independent triplicate experiments (n=3). ***P≤0.001, 
**P≤0.01, *P≤0.05. †††P≤0.001, ††P≤0.01, †P≤0.05, and ns indicates not significant.
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Figure VI in the online-only Data Supplement). However, 
the inhibition of the Ras-Raf-MEK pathway but not the inhi-
bition of PI3K/Akt and p38 MAPK could be overcome by 
VEGF stimulation. Thus, VEGF regulates the interaction of 
HDL with endothelial cells by activating PI3K/Akt and p38 
MAPK but not the Ras-Raf-MEK pathway. PI3K is known to 
be involved in endosomal membrane trafficking,31,32 and its 
inhibition by wortmannin in polarized cells affects early traf-
ficking in the endocytic pathway, as well as inward vesicu-
larization for the formation of multivesicular bodies in the 
later stages.33 For example, PI3K was shown to mediate the 
stimulatory effect of insulin on the cell surface translocation 
of the glucose transporter-4.32,34 It has also been shown in 
hepatocytes that insulin regulates the cell surface expression 
of SR-BI and selective lipid uptake dependent on PI3K acti-
vation.35 VEGF-A is known to stimulate actin reorganization, 
which in turn contributes to HDL uptake5 and cell migration 
depending on activation of p38 MAPK but not ERK1/2 MAP 
kinase.36,37 Thus, it will be interesting to identify agonists 
beyond VEGF that regulate the endothelial binding, uptake, 
and transport of HDL by activating the MEK pathway. In this 
regard, it is also important to note our finding that RNA inter-
ference with MEK but not with Akt inhibited the binding and 
association of LDL with endothelial cells (Figure VII in the 
online-only Data Supplement).
We found that in HAECs, VEGF-A is required for the 
translocation of SR-BI from intracellular compartments to the 
cell surface, which in turn facilitates the binding, uptake, and 
transport of HDL (Figures 4 and 5). Similarly the cell-surface 
translocation of SR-BI is enhanced by insulin in hepatocytes35 
and by both insulin and angiotensin-II in adipocytes.38In 
hepatocytes, cell surface expression of SR-BI was shown to 
be dependent on PDZK1,39 which is a tissue-specific adap-
tor protein with 4 PDZ domains (named after 3 proteins con-
taining such domains: postsynaptic density protein [PSD95], 
Drosophila discs large [Dlg], and the tight junction protein 
zonula occludens-1 [ZO-1]). However, in our hands, interfer-
ence with PDZK1 did not limit the binding of HDL (data not 
shown) indirectly, confirming that in endothelial cells, target-
ing of SR-BI to the plasma membrane does not depend on 
PDZK1.40
SR-BI has been shown to be involved in the protective 
effects of HDL on the endothelium, namely angiogenesis, 
migration, activation of endothelial nitric oxide synthase, and 
monocyte adhesion.41 Recent studies have shown the associa-
tion of enhanced expression of SR-BI expression in endothe-
lial cells with decreased atherosclerosis in mice.42 Thus, the 
requirement of VEGF on maintaining cell surface expression 
of SR-BI may have vascular effects beyond regulating tran-
sendothelial lipoprotein transport.
Figure 4. Vascular endothelial growth factor (VEGF)-A regulates cell surface expression of scavenger receptor BI (SR-BI). Western blots 
of SR-BI, low-density lipoprotein (LDL) receptor, ATP binding cassette transporter ABCG1, endothelial lipase (EL), and anti-TATA-binding 
protein (TBP) in total cell lysates (left) and on the cell surface (right). Human aortic endothelial cells (HAECs) were cultured in the pres-
ence or absence of VEGF for 72 hours, and cells were then pretreated with 25 ng/mL of VEGF165 for 1 hour if indicated. The Western blot 
was probed with anti-SR-BI (82 kDa), anti-LDLR (95 and 160 kDa), anti-ABCG1 (90 kDa), as well as anti–endothelial lipase (EL; 60 kDa) 
and anti–TATA-binding protein (TBP; 40 kDa, as control for intracellular protein expression).
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HDL was previously reported to enhance hypoxia-
induced angiogenesis by stimulating the expression of VEGF 
and VEGFR2 in endothelial cells by a mechanism involving 
SR-BI.43,44 It, thus, seems that in endothelial cells, HDL and 
SR-BI are both upstream regulators and downstream targets of 
the VEGF/VEGFR2 system.
We confirmed previous reports3,10–13 that endothelial cells 
internalize and transcytose LDL. We also confirmed the pre-
vious report of Armstrong et al12 that this process involves 
SR-BI (Velagapudi, Rohrer, von Eckardstein, unpublished 
observations). However, despite regulating the cell surface 
abundance of SR-BI, VEGF does not regulate the transen-
dothelial transport of LDL. Neither the interference with 
the VEGF receptors by drugs or RNAi nor the removal or 
addition of VEGF had any significant effect on the binding, 
uptake, or transport of LDL by HAECs. These lipoprotein-
specific effects of VEGF on the processing of HDL and LDL 
by HAECs indicate the existence of additional regulators and 
routes of transendothelial transport, for example, activin-like 
kinase 1, which was recently identified by a genome-wide 
RNAi-screen as an endothelial LDL-binding protein mediat-
ing uptake and transcytosis of LDL.13
From a more general perspective, our findings provide 
further evidence that transendothelial lipoprotein transport 
occurs by regulated processes3,6–8,12,13 rather than passive fil-
tration.4 Dys-regulated transendothelial lipoprotein transport 
Figure 5. Vascular endothelial growth factor (VEGF)-A modulates scavenger receptor BI (SR-BI)–dependent binding, association, and 
transport of high-density lipoprotein (HDL) by human aortic endothelial cells (HAECs). HAECs were transfected with a specific siRNA 
against SR-BI or with nonsilencing control siRNA (NS control) in the presence or absence of VEGF-A-containing medium, and assays 
were performed 72 hours posttransfection. A, Specific binding was measured by incubating cells with 125I-HDL at 4°C. B, Specific cell 
association was analyzed by incubating cells with 125I-HDL at 37°C. C, ECs were cultured on inserts, and transport of 125I-HDL from the 
apical to basolateral compartment was measured at 37°C. The results are represented as mean±SEM of 3 independent triplicate experi-
ments (n=3). ***P≤0.001, **P≤0.01, *P≤0.05.
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may influence the pathogenesis of atherosclerosis beyond 
plasma levels of LDL and HDL. In fact, it was recently shown 
in LDL receptor–deficient mice that acute lowering of LDL 
cholesterol with anti-ApoB antisense oligonucleotides rap-
idly reduces the permeability of the aortic endothelium for 
LDL and causes regression of atherosclerosis independently 
of LDL pool size.45 It is less obvious how changes in arte-
rial permeability for HDL may affect atherosclerosis. At first 
sight, increased availability of HDL in the subendothelium 
will be protective, for example, by enhancing cholesterol 
efflux from macrophage foam cells. However, this will only 
be effective if HDL also leave the arterial wall to conclude 
reverse cholesterol transport. Disturbed egress of HDL from 
the arterial wall, potentially via the lymphatics,24,25 will lead to 
the accumulation of HDL in the arterial wall. These particles 
will be eventually oxidized and become dysfunctional46,47 and, 
thereby, promote rather than inhibit cholesterol accumulation 
and, hence, atherosclerosis.
In conclusion, we here showed that the VEGF-A/VEGFR2 
regulates endothelial binding, uptake, and transport of HDL 
through PI3K/Akt and p38 MAPK and, as the final result, cell 
surface expression of SR-BI. Thereby, VEGF-A may play an 
important regulatory role for the vascular protective effects of 
HDL, as well as reverse cholesterol transport.
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Highlights
• Vascular endothelial growth factor (VEGF)-A stimulates the binding, uptake, and transcellular transport of high-density lipoprotein but not low-
density lipoprotein by aortic endothelial cells.
• These stimulatory effects of VEGF-A require VEGF receptor 2 but neither VEGF receptor 1 nor VEGF receptor 3.
• These stimulatory effects of VEGF-A involve phosphatidyl-inositol 3 kinase/protein kinase B and p38 mitogen-activated protein kinase as well 
as scavenger receptor BI.
• VEGF-A stimulates the translocation of scavenger receptor BI to the plasma membrane.
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Supplementary Figure I 
 
 
  
         
    
 
Supplementary Figure I: Expression of VEGF receptors (A) and efficiency of RNA interference 
(B, C) 
A, mRNA levels of VEGFR1, VEGFR2 and VEGFR3 in HAECs were measured by real-time 
polymerase chain reaction. HAECs were transfected with specific siRNA against VEGFR1, VEGFR2, 
or VEGFR3 or with non-silencing control siRNA (NS control). Assays were performed 72hours after 
transfection. Silencing efficiency was analyzed at the B, mRNA level using qRT-PCR and C, protein 
level using western blotting. The western blots were probed with antibodies against VEGFR1 (180 
kDa), VEGFR2 (210 kDa, 230 kDa) and VEGFR3 (195 kDa) respectively and Beta-actin (42 kDa) was 
used as the loading control. 
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Supplementary Figure II 
 
 
 
Supplementary Figure II: Effect of VEGF receptors on the uptake of HDL (left lane) and LDL (right 
lane) by HAECs 
HAECs were transfected with a specific siRNA against VEGFR2 or with non-silencing control siRNA 
(NS control) and fluorescent lipoprotein uptake assay was performed 72hours after transfection. Uptake 
of Atto594-HDL (red) and Atto488-LDL (green) into transfected endothelial cells was analyzed by wide-
field fluorescence microscopy. ECs were incubated with 50ug/ml of Atto594-HDL or 50ug/ml Atto488-
LDL for 1hour prior to fixation and nuclei were counterstained with DAPI (blue). Scale bar is 20µM. 
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Supplementary Figure III 
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Supplementary Figure III:  Effect of VEGF-A on HAECs proliferation (A) and phosphorylation of 
VEGFR2 and its downstream kinases (B). HAECs were cultured in regular medium containing  VEGF-
A (control) or in medium free of VEGF-A (no VEGF) for 72hours or cells were pre-treated with 25ng/ml 
of VEGF165 for 1hour prior to protein extraction. A: The rate of cell proliferation was analyzed using the 
MTT assay. The results are representative of three individual experiments (n=3). B: Cell lysates were 
analysed by western blotting for phospho VEGFR2 (Tyrosine 1054/1059) and total VEGFR2, phospho 
Akt (Ser-473) and total Akt, phospho p38 MAPK (Thr180/Tyr182 ) and total p38 MAPK, phospho  
ERK1/2 (Thr202/Tyr204 & Thr185/Tyr187) and total ERK1/2 
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Supplementary Figure IV 
 
                    
 
Supplementary Figure IV: Effect of VEGF-A treatment on HDL (left lane) and LDL (right lane) 
uptake by HAECs 
HAECs were cultured in the presence of VEGF-A (control) or absence of VEGF-A (no VEGF) for 72hours 
or cells were pre-treated with 25ng/ml of VEGF165 for 1hour prior to the incubation with fluorescent 
lipoproteins. ECs were incubated with 50ug/ml of Atto594-HDL or Atto488-LDL for 1hour prior to fixation 
and nuclei were counterstained with DAPI (blue). Uptake of Atto594-HDL (red) and Atto488-LDL (green) 
in endothelial cells was analyzed by wide-field microscopy. Scale bar is 20µM. 
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Supplementary Figure V 
 
 
 
 
Supplementary Figure V: Silencing efficiency of AKT, p38 MAPK and MEK1/2 
Protein levels of Akt, p38 MAPK and MEK1/2 were measured using western blotting following 
transfection of ECs with specific siRNAs against AKT, MAPK14 (p38 MAPK), MAP2K1/MAP2K2 
(MEK1/2). TATA-binding protein (TBP) was used as a loading control.  
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Supplementary Figure VI 
 
                         
  
 
                        
 
Supplementary Figure VI: VEGF-A regulates HDL binding and association through PI3K/Akt and 
p38 MAPK 
HAECs were transfected with specific siRNA against AKT or MAPK14 (p38 MAPK) or MAP2K1/MAP2K2 
(MEK1/2) or with non-silencing control (NS control) siRNA in the presence or absence of VEGF-A 
containing medium and assays were performed 72hours post-transfection. A, Specific binding was 
measured by incubating cells with 125I-HDL at 4 ºC. B, Specific cell association was analyzed by 
incubating cells with 125I-HDL at 37 ºC. The results are represented as mean±SEM and three 
independent triplicate experiments (n=3). ***P≤ 0.001, **P≤ 0.01, *P≤ 0.05  
†††P≤ 0.001, ††P≤ 0.01, †P≤ 0.05 and ns represents “not significant” 
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Supplementary Figure VII 
 
 
 
Supplementary Figure VII: Binding and association of 125I-LDL through p38 MAPK and MEK1/2 
HAECs were transfected with specific siRNA against AKT or MAPK14 (p38 MAPK) or MAP2K1/MAP2K2 
(MEK1/2) or with non-silencing control (NS control) siRNA in the presence of VEGF-A    containing 
medium and assays were performed 72hours post-transfection. A, Specific binding was measured by 
incubating cells with 125I-LDL at 4 ºC. B, Specific cell association was analyzed by incubating cells with 
125I-LDL at 37 ºC. The results are represented as mean±SEM and three independent triplicate 
experiments (n=3). ***P≤ 0.001, **P≤ 0.01, *P≤ 0.05 and ns represents “not significant” 
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Supplementary Figure VIII 
 
 
 
 
 
Supplementary Figure VIII: Efficiency of silencing SR-BI 
A, mRNA levels of SR-BI were analyzed following transfection of ECs with specific siRNAs against SR-
BI. GAPDH was used as a housekeeping control. B, SR-BI (82 kDa) protein expression levels measured 
by western blotting, GAPDH (38 kDa) used as loading control.   
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Supplementary Tables 
 
 
Supplementary Table I: List of kinase drug inhibitors used in the drug screening to study their effect 
on Atto 594-LDL cellular uptake in HAECs. For each drug interaction, nHill represents the Hill 
coefficient for the curve which is the measure of the slope at IC50, qualified AC50 (qAC50) represents 
a reliable value based on computed IC50, median residual activity was calculated relative to a control 
reaction in the presence of vehicle (DMSO) and standard error of the residual activity at the maximal 
drug concentration, represents a measure of screen reproducibility. 
 
Supplementary Table II: List of kinase drug inhibitors used in the drug screening to study their effect 
on Atto 594-HDL cellular uptake in HAECs. For each drug interaction, nHill represents the Hill 
coefficient for the curve which is the measure of the slope at IC50, qualified AC50 (qAC50) represents 
a reliable value based on computed IC50, median residual activity was calculated relative to a control 
reaction in the presence of vehicle (DMSO) and standard error of the residual activity at the maximal 
drug concentration, represents a measure of screen reproducibility. 
 
 
Compound CAS number Target nHill qAC50 Residual activity (Median) Standard error 
ABT‐869(Linifanib) 796967‐16‐3 VEGFR  Inactive 0.005328 104.44 2.534
AC‐220 950769‐58‐1 FLT‐3 Inactive 0.003567 95.78 1.451
AEE788 497839‐62‐0 EGFR | HER1/2 | VEGFR |  Flt‐1 Inactive 0.004539 64.81 2.337
AG‐490 133550‐30‐8 EGFR | JAK Inactive 0.006796 73.27 3.79
AP24534 943319‐70‐8 VEGFR | FGFR | FLT‐3 Inactive 0.000751 85.12 4.951
AS‐605240 648450‐29‐7 PI3K Inactive 0.007774 113.43 2.486
AS703026 1236699‐92‐5 MEK Inactive 0.004638 117.35 2.297
AT7519 844442‐38‐2 CDK Inactive 0.005232 109.26 0.9898
AT7867 857531‐00‐1 Akt  Inactive 0.00592 69.82 4.245
AT9283 896466‐04‐9 Aurora | JAK | ABL 4 0.005243 53.86 1.961
Aurora A Inhibitor I 1158838‐45‐9 Aurora Inactive 0.003401 98.29 4.403
AV‐951(Tivozanib) 475108‐18‐0 VEGFR Inactive 0.004397 61.33 2.864
Axitinib 319460‐85‐0 VEGFR Inactive 0.005175 95.89 1.096
AZD0530(Saracatinib) 379231‐04‐6 ABL Inactive 0.00369 83.31 1.971
AZD1152‐HQPA(Barasertib) 722544‐51‐6 Aurora Inactive 0.00394 107.66 0.8166
AZD1480 935666‐88‐9 JAK Inactive 0.005735 122.35 2.616
AZD6244(Selumetinib) 606143‐52‐6 MEK Inactive 0.00437 108.08 2.115
AZD6482 1173900‐33‐8 PI3K Inactive 0.004897 118.33 1.417
AZD7762 860352‐01‐8 CHK Inactive 0.005518 100.01 1.221
AZD8055 1009298‐09‐2 mTOR Inactive 0.004296 99.19 1.278
AZD8330 869357‐68‐6 MEK Inactive 0.004336 106.09 1.822
BAY 73‐4506(Regorafenib) 755037‐03‐7 c‐KIT | VEGFR Inactive 0.004142 81.60 1.229
BEZ235 915019‐65‐7 PI3K | mTOR Inactive 0.00426 104.15 1.282
BI 2536 755038‐02‐9 PLK Inactive 0.003834 67.68 2.508
BIBF1120(Vargatef) 928326‐83‐4 FGFR | VEGFR Inactive 0.003706 87.94 2.495
BIBW2992(Tovok) 439081‐18‐2 EGFR | HER2 Inactive 0.004116 66.37 1.713
BIRB 796 285983‐48‐4 p38 MAPK Inactive 0.00379 93.51 1.323
BIX 02188 1094614‐84‐2 MEK Inactive 0.004689 91.61 1.616
BIX 02189 1094614‐85‐3 MEK Inactive 0.00454 85.92 1.435
BMS 777607 1196681‐44‐3 c‐Met Inactive 0.003899 100.34 3.856
BMS 794833 1174046‐72‐0 VEGFR | c‐Met | FLT‐3 1.350289 0.004266 62.14 3.195
BMS‐599626 8173837‐23‐1 EGFR | HER2 Inactive 0.003527 73.23 3.586
Bosutinib(SKI‐606) 380843‐75‐4 ABL 0.5 0.00377 66.01 4.61
BS‐181 hydrochloride 1397219‐81‐6  CDK 1.32514 0.003827 30.11 1.637
CCT129202 942947‐93‐5 Aurora Inactive 0.004024 114.75 0.897
Cediranib(AZD2171) 288383‐20‐0 VEGFR 2.474041 0.004439 79.11 1.401
CHIR‐99021 252917‐06‐9 GSK‐3 Inactive 0.004298 111.74 1.227
CI‐1033(Canertinib) 267243‐28‐7 HER2 | EGFR 1.463127 0.002188 29.41 3.074
CI‐1040 (PD184352) 212631‐79‐3 MEK Inactive 0.004178 89.34 1.664
Colchicine 64‐86‐8 Tubulin (used as control) 0.83 9.99E‐06 57.68 2.091
CP‐724714 537705‐08‐1 HER2 Inactive 0.00426 101.02 2.833
CYC116 693228‐63‐6 Aurora | VEGFR 3.49107 0.005154 50.61 1.846
Dasatinib 302962‐49‐8 ABL Inactive 0.004098 104.94 1.381
Deforolimus(MK‐8669) 572924‐54‐0 mTOR Inactive 0.00202 70.34 4.036
ENMD‐2076 934353‐76‐1 Aurora | Flt‐3 | VEGFR | FGFR 4 0.003805 55.25 1.475
Enzastaurin 170364‐57‐5 PKC Inactive 0.003879 97.22 1.369
Erlotinib Hydrochloride 183319‐69‐9 EGFR Inactive 0.004652 95.45 5.355
Everolimus(RAD001) 159351‐69‐6 mTOR Inactive 0.002087 78.45 2.934
Flavopiridol(Alvocidib) 146426‐40‐6 CDK Inactive 0.004977 101.98 3.17
GDC‐0879 905281‐76‐7 RAF Inactive 0.005981 107.27 2.613
GDC‐0941 957054‐30‐7 PI3K 0.773247 0.003894 70.96 1.355
Gefitinib(Iressa) 184475‐35‐2 EGFR | Akt Inactive 0.004475 98.17 1.34
GSK1059615 958852‐01‐1 PI3K | mTOR Inactive 0.005999 91.91 1.197
GSK461364 929095‐18‐1 PLK 0.932748 0.003679 67.68 1.823
Hesperadin 422513‐13‐1 Aurora Inactive 0.003871 117.94 1.403
HMN‐214 173529‐46‐9 PLK Inactive 0.004712 78.79 3.22
IC‐87114 371242‐69‐2 PI3K Inactive 0.005032 77.10 3.902
Imatinib Mesylate 220127‐57‐1 c‐Kit Inactive 0.003392 93.35 2.728
Imatinib(STI571) 152459‐95‐5 VEGFR Inactive 0.004052 96.58 2.842
Indirubin 479‐41‐4 GSK‐3 Inactive 0.007626 105.11 1.099
JNJ‐38877605 943540‐75‐8 c‐Met Inactive 0.0053 112.36 1.294
JNJ‐7706621 443797‐96‐4 Aurora / CDK 0.985232 0.005072 87.13 1.105
Ki8751 228559‐41‐9 c‐Kit | VEGFR | FGFR Inactive 0.004261 89.31 2.658
KRN 633 286370‐15‐8 VEGFR Inactive 0.004798 95.96 3.172
KU‐0063794 938440‐64‐3 mTOR Inactive 0.004296 93.50 3.103
KU‐55933 587871‐26‐9 ATM Inactive 0.005057 46.10 2.876
KU‐60019 925701‐49‐1 ATM 1.329854 0.003652 49.01 1.486
Supplementary Table I
KW 2449 1000669‐72‐6 FLT‐3 | ABL | Aurora Inactive 0.006017 93.96 4.683
Lapatinib Ditosylate 388082‐77‐7 EGFR | HER2 Inactive 0.002161 107.82 1.222
LY2228820 862507‐23‐1 p38 MAPK Inactive 0.003264 88.96 1.558
LY2784544 1229236‐86‐5 JAK Inactive 0.004256 124.76 2.605
LY294002 154447‐36‐6 PI3K  Inactive 0.006507 104.73 2.668
Masitinib(AB1010) 790299‐79‐5 c‐Kit | FGFR | VEGF 1.658041 0.002381 20.79 2.985
MGCD‐265 875337‐44‐3 c‐Met | VEGFR | Tie‐2 Inactive 0.003864 105.43 1.658
MK‐2206 1032350‐13‐2 Akt Inactive 0.004163 103.46 1.895
MLN8237 1028486‐01‐2 Aurora Inactive 0.003854 112.75 2.064
Motesanib Diphosphate 857876‐30‐3 VEGFR | PDGFR | Src Inactive 0.003512 108.22 4.405
MP‐470 850879‐09‐3 c‐Kit | c‐Met | FLT‐3 Inactive 0.004469 81.09 1.33
Neratinib 698387‐09‐6 HER2 0.982039 0.000981 27.53 1.256
Nilotinib 641571‐10‐0 ABL Inactive 0.003777 88.81 2.476
NVP‐ADW742 475488‐23‐4 IGF‐1R 1.830101 0.002036 20.36 1.654
NVP‐TAE684 761439‐42‐3 ALK Inactive 0.003256 101.89 1.703
ON‐01910 1225497‐78‐8 PLK 0.5 0.004224 63.38 1.907
OSI‐930 728033‐96‐3 c‐Kit | VEGFR Inactive 0.00451 97.12 1.02
Pazopanib Hydrochloride 635702‐64‐6 VEGFR Inactive 0.00422 66.52 1.706
PD0325901 391210‐10‐9 MEK Inactive 0.004148 100.07 3.427
PD0332991 571190‐30‐2 CDK Inactive 0.004469 81.42 0.8376
PD153035 hydrochloride 183322‐45‐4 EGFR Inactive 0.005042 93.13 2.898
PD318088 391210‐00‐7 MEK Inactive 0.003564 99.32 1.363
PD98059 167869‐21‐8 MEK Inactive 0.007483 99.51 0.6507
Pelitinib 257933‐82‐7 EGFR Inactive 0.004274 83.19 1.65
PF‐04217903 956905‐27‐4 c‐Met Inactive 0.005371 102.16 2.132
PF‐2341066 877399‐52‐5 c‐Met | ALK 2.685256 0.002787 23.22 3.008
PHA‐680632 398493‐79‐3 Aurora Inactive 0.003987 83.88 1.548
PHA‐739358(Danusertib) 827318‐97‐8 Aurora | ABL Inactive 0.004214 111.40 4.365
PHA‐793887 718630‐59‐2 CDK Inactive 0.005533 116.61 3.269
PI‐103 371935‐74‐9 PI3K | mTOR Inactive 0.005741 57.40 1.049
PIK‐293 900185‐01‐5 PI3K Inactive 0.005032 82.23 3.32
PIK‐75 Hydrochloride 372196‐77‐5 PI3K Inactive 0.004092 97.86 1.717
PIK‐90 677338‐12‐4 PI3K Inactive 0.005692 105.53 2.201
PIK‐93 593960‐11‐3 PI3K Inactive 0.00513 110.54 1.635
PLX‐4720 918505‐84‐7 RAF Inactive 0.004833 114.53 1.222
Quercetin(Sophoretin) 117‐39‐5 PI3K | PKC Inactive 0.006617 105.81 1.439
R406 841290‐81‐1 Syk Inactive 0.003182 107.39 1.344
R406(free base) 841290‐80‐0 Syk Inactive 0.004251 107.15 1.487
RAF265 927880‐90‐8 RAF| VEGFR Inactive 0.003858 93.09 1.718
Rapamycin(Sirolimus) 53123‐88‐9 mTOR Inactive 0.002188 109.89 2.509
Roscovitine(CYC202) 186692‐46‐6 CDK Inactive 0.005643 106.75 1.782
SB 202190 152121‐30‐7 p38 MAPK Inactive 0.006036 97.11 1.683
SB 203580 152121‐47‐6 p38 MAPK 1.140681 0.005299 80.54 1.644
SB 216763 280744‐09‐4 GSK‐3 Inactive 0.005388 107.30 0.8033
SB 431542 301836‐41‐9 ALK Inactive 0.005203 67.24 3.57
SB 525334 356559‐20‐1 ALK  Inactive 0.005824 89.56 4.03
SGX‐523 1022150‐57‐7 c‐Met Inactive 0.005565 106.20 1.444
SNS‐032(BMS‐387032) 345627‐80‐7 CDK Inactive 0.005256 103.27 1.636
SNS‐314 Mesylate 1057249‐41‐8 Aurora 1.743522 0.002217 26.41 2.724
Sorafenib Tosylate 475207‐59‐1 VEGFR | RAF | MEK 2.489475 0.002209 30.23 2.589
SP600125 129‐56‐6 JNK Inactive 0.009082 108.28 4.468
SU11274(PKI‐SU11274) 658084‐23‐2 c‐Met 0.59355 0.003521 45.65 0.9738
Sunitinib Malate 341031‐54‐7 FLT‐3 | VEGFR | Kit 1.858937 0.003755 74.73 1.143
Tandutinib (MLN518) 387867‐13‐2 FLT‐3 | c‐KIT Inactive 0.003554 72.58 1.502
Temsirolimus 162635‐04‐3 mTOR Inactive 0.001941 77.26 1.683
TG100‐115 677297‐51‐7 PI3K Inactive 0.005775 97.79 0.89
TGX‐221 663619‐89‐4 PI3K Inactive 0.005488 96.74 3.572
TSU‐68 252916‐29‐3 VEGFR | FGFR Inactive 0.006444 100.62 3.294
U0126‐EtOH 1173097‐76‐1 MEK Inactive 0.004689 106.00 1.296
Vandetanib 443913‐73‐3 VEGFR | EGFR  1.393366 0.004207 61.62 2.716
Vatalanib 212141‐51‐0 VEGFR | c‐Kit | FLT‐3 Inactive 0.004765 85.99 2.543
Vinorelbine(Navelbine) 71486‐22‐1 p38 MAPK 1.117829 8.11E‐07 42.42 4.42
VX‐680 639089‐54‐6 Aurora Inactive 0.004305 76.51 0.9318
VX‐702 479543‐46‐9 p38 MAPK Inactive 0.004947 91.18 3.594
VX‐745 209410‐46‐8 p38 MAPK Inactive 0.004584 89.65 7.681
WYE‐354 1062169‐56‐5 mTOR Inactive 0.004036 79.09 1.378
WZ3146 1214265‐56‐1 EGFR Inactive 0.004302 90.65 0.8991
WZ4002 1213269‐23‐8 EGFR Inactive 0.004041 104.65 1.124
WZ8040 1214265‐57‐2 EGFR 1.141569 0.004158 55.28 1.323
XL147 956958‐53‐5 PI3K Inactive 0.004459 102.91 1.96
XL184 849217‐68‐1 c‐Met | FLT‐3 | VEGFR | c‐KIT Inactive 0.003988 94.78 1.664
XL765 1123889‐87‐1 PI3K Inactive 0.003335 110.36 0.9356
XL880(GSK1363089) 849217‐64‐7 c‐Met | VEGFR 1.658425 0.00265 33.19 4.216
ZM‐447439 331771‐20‐1 Aurora Inactive 0.003894 90.86 1.728
ZSTK474 475110‐96‐4 PI3K Inactive 0.004791 98.86 0.9774
Compound ID CAS number Target nHill qAC50 Residual activity (Median) Standard error 
ABT‐869(Linifanib) 796967‐16‐3 VEGFR  Inactive 0.005328 111.40 1.942
AC‐220 950769‐58‐1 FLT‐3 1.436358 0.000172 85.88 1.661
AEE788 497839‐62‐0 EGFR | HER1/2 | VEGFR |  Flt‐1 0.5 0.004539 64.52 5.119
AG‐490 133550‐30‐8 EGFR | JAK Inactive NA 62.46 2.87
AP24534 943319‐70‐8 VEGFR | FGFR | FLT‐3 Inactive NA 51.61 5.275
AS‐605240 648450‐29‐7 PI3K Inactive 0.007774 116.43 3.648
AS703026 1236699‐92‐5 MEK Inactive 0.004638 105.53 3.084
AT7519 844442‐38‐2 CDK Inactive 0.005232 104.77 1.734
AT7867 857531‐00‐1 Akt  0.606294 0.00592 70.96 4.514
AT9283 896466‐04‐9 Aurora | JAK | ABL Inactive 0.005243 49.39 5.075
Aurora A Inhibitor I 1158838‐45‐9 Aurora Inactive 0.003401 95.01 4.459
AV‐951(Tivozanib) 475108‐18‐0 VEGFR Inactive 0.004397 69.21 5.143
Axitinib 319460‐85‐0 VEGFR 0.5 0.005175 60.78 1.488
AZD0530(Saracatinib) 379231‐04‐6 ABL 0.637742 0.00369 51.85 2.335
AZD1152‐HQPA(Barasertib) 722544‐51‐6 Aurora Inactive 0.00394 105.80 2.339
AZD1480 935666‐88‐9 JAK 2.48508 0.005735 142.14 2.618
AZD6244(Selumetinib) 606143‐52‐6 MEK Inactive 0.00437 96.22 2.489
AZD6482 1173900‐33‐8 PI3K Inactive 0.004897 131.95 1.131
AZD7762 860352‐01‐8 CHK Inactive 0.005518 127.72 1.749
AZD8055 1009298‐09‐2 mTOR Inactive 0.004296 102.97 1.692
AZD8330 869357‐68‐6 MEK Inactive 0.004336 101.27 3.425
BAY 73‐4506(Regorafenib) 755037‐03‐7 c‐KIT | VEGFR 0.5 0.003432 62.47 3.282
BEZ235 915019‐65‐7 PI3K | mTOR Inactive 0.00426 128.01 1.958
BI 2536 755038‐02‐9 PLK 0.5 0.001663 61.08 4.656
BIBF1120(Vargatef) 928326‐83‐4 FGFR | VEGFR 2.337782 2.24E‐05 53.12 2.551
BIBW2992(Tovok) 439081‐18‐2 EGFR | HER2 0.5 0.003091 50.84 4.105
BIRB 796 285983‐48‐4 p38 MAPK Inactive 0.00379 94.18 1.4
BIX 02188 1094614‐84‐2 MEK 0.5 0.004689 69.52 1.975
BIX 02189 1094614‐85‐3 MEK 1.406958 0.00454 68.90 1.77
BMS 777607 1196681‐44‐3 c‐Met Inactive NA 81.06 5.612
BMS 794833 1174046‐72‐0 VEGFR | c‐Met | FLT‐3 0.67305 0.004266 69.82 5.162
BMS‐599626 8173837‐23‐1 EGFR | HER2 3.623089 0.003527 96.94 4.239
Bosutinib(SKI‐606) 380843‐75‐4 ABL 0.5 0.002486 50.52 5.168
BS‐181 hydrochloride 1397219‐81‐6  CDK Inactive NA 28.92 2.644
CCT129202 942947‐93‐5 Aurora Inactive 0.004024 99.49 1.772
Cediranib(AZD2171) 288383‐20‐0 VEGFR 0.695237 0.002018 48.94 2.098
CHIR‐99021 252917‐06‐9 GSK‐3 Inactive 0.004298 101.87 2.837
CI‐1033(Canertinib) 267243‐28‐7 HER2 | EGFR 0.797796 0.001326 38.08 5.456
CI‐1040 (PD184352) 212631‐79‐3 MEK 4 6.62E‐06 47.43 1.867
Colchicine 64‐86‐8 Tubulin (used as control) 0.8 9.74E‐06 58.11 1.419
CP‐724714 537705‐08‐1 HER2 Inactive 0.00426 104.76 4.142
CYC116 693228‐63‐6 Aurora | VEGFR 2.599212 0.002925 20.33 4.053
Dasatinib 302962‐49‐8 ABL Inactive 0.004098 91.41 2.37
Deforolimus(MK‐8669) 572924‐54‐0 mTOR Inactive NA 56.18 3.082
ENMD‐2076 934353‐76‐1 Aurora | Flt‐3 | VEGFR | FGFR 1.654872 0.002733 38.09 2.029
Enzastaurin 170364‐57‐5 PKC Inactive 0.003879 99.63 1.711
Erlotinib Hydrochloride 183319‐69‐9 EGFR 4 4.07E‐07 70.95 6.794
Everolimus(RAD001) 159351‐69‐6 mTOR Inactive NA 73.76 2.527
Flavopiridol(Alvocidib) 146426‐40‐6 CDK Inactive NA 65.94 4.419
GDC‐0879 905281‐76‐7 RAF Inactive 0.005981 113.93 4.043
GDC‐0941 957054‐30‐7 PI3K 2.627782 0.002188 19.21 1.756
Gefitinib(Iressa) 184475‐35‐2 EGFR | Akt Inactive 0.004475 124.05 2.182
GSK1059615 958852‐01‐1 PI3K | mTOR Inactive 0.005999 89.96 2.697
GSK461364 929095‐18‐1 PLK 0.580974 0.000844 39.78 3.107
Hesperadin 422513‐13‐1 Aurora 1.315694 5.01E‐05 149.34 1.415
HMN‐214 173529‐46‐9 PLK 0.5 0.004712 76.33 5.656
IC‐87114 371242‐69‐2 PI3K Inactive NA 55.96 3.487
Imatinib Mesylate 220127‐57‐1 c‐Kit 0.5 0.003392 92.22 3.616
Imatinib(STI571) 152459‐95‐5 VEGFR Inactive 0.004052 102.13 3.291
Indirubin 479‐41‐4 GSK‐3 Inactive 0.007626 119.93 2.1
JNJ‐38877605 943540‐75‐8 c‐Met Inactive 0.0053 103.29 1.764
JNJ‐7706621 443797‐96‐4 Aurora / CDK Inactive 0.005072 92.60 2.659
Ki8751 228559‐41‐9 c‐Kit | VEGFR | FGFR Inactive NA 65.93 3.54
KRN 633 286370‐15‐8 VEGFR 4 0.00096 63.98 2.755
KU‐0063794 938440‐64‐3 mTOR Inactive 0.004296 96.81 3.788
KU‐55933 587871‐26‐9 ATM Inactive NA 30.02 3.853
KU‐60019 925701‐49‐1 ATM 4 0.003652 44.93 2.368
Supplementary Table II
KW 2449 1000669‐72‐6 FLT‐3 | ABL | Aurora 0.5 0.006017 89.39 5.942
Lapatinib Ditosylate 388082‐77‐7 EGFR | HER2 Inactive 0.002161 105.91 1.289
LY2228820 862507‐23‐1 p38 MAPK Inactive 0.003264 88.18 1.962
LY2784544 1229236‐86‐5 JAK Inactive 0.004256 124.83 2.689
LY294002 154447‐36‐6 PI3K  3.774832 0.006507 110.19 3.435
Masitinib(AB1010) 790299‐79‐5 c‐Kit | FGFR | VEGF 0.5 0.002422 28.02 6.116
MGCD‐265 875337‐44‐3 c‐Met | VEGFR | Tie‐2 0.5 0.003512 70.10 2.341
MK‐2206 1032350‐13‐2 Akt Inactive 0.004163 80.04 4.248
MLN8237 1028486‐01‐2 Aurora Inactive 0.003854 93.55 2.406
Motesanib Diphosphate 857876‐30‐3 VEGFR | PDGFR | Src 4 0.003512 100.69 4.224
MP‐470 850879‐09‐3 c‐Kit | c‐Met | FLT‐3 Inactive 0.004469 78.92 2.749
Neratinib 698387‐09‐6 HER2 4 0.000432 30.20 2.01
Nilotinib 641571‐10‐0 ABL Inactive 0.003777 97.63 3.206
NVP‐ADW742 475488‐23‐4 IGF‐1R 1.690275 0.000264 33.84 3.012
NVP‐TAE684 761439‐42‐3 ALK Inactive 0.003256 106.20 2.016
ON‐01910 1225497‐78‐8 PLK 1.191079 5.85E‐05 69.64 2.724
OSI‐930 728033‐96‐3 c‐Kit | VEGFR Inactive 0.00451 85.38 2.42
Pazopanib Hydrochloride 635702‐64‐6 VEGFR 1.323082 0.00422 58.02 1.478
PD0325901 391210‐10‐9 MEK Inactive 0.004148 99.74 4.176
PD0332991 571190‐30‐2 CDK 4 9.03E‐07 36.16 1.822
PD153035 hydrochloride 183322‐45‐4 EGFR 0.5 0.005042 77.89 2.34
PD318088 391210‐00‐7 MEK Inactive 0.003564 98.15 1.448
PD98059 167869‐21‐8 MEK Inactive 0.007483 112.56 1.394
Pelitinib 257933‐82‐7 EGFR 1.28075 0.000135 57.97 2.581
PF‐04217903 956905‐27‐4 c‐Met Inactive 0.005371 104.95 4.045
PF‐2341066 877399‐52‐5 c‐Met | ALK 1.093137 0.001765 30.19 3.104
PHA‐680632 398493‐79‐3 Aurora 0.627183 0.003987 63.42 2.356
PHA‐739358(Danusertib) 827318‐97‐8 Aurora | ABL 4 0.004214 139.90 3.855
PHA‐793887 718630‐59‐2 CDK Inactive 0.005533 129.45 4.285
PI‐103 371935‐74‐9 PI3K | mTOR Inactive NA 45.49 2.69
PIK‐293 900185‐01‐5 PI3K Inactive NA 71.33 3.889
PIK‐75 Hydrochloride 372196‐77‐5 PI3K Inactive 0.004092 101.69 4.919
PIK‐90 677338‐12‐4 PI3K Inactive 0.005692 93.77 3.314
PIK‐93 593960‐11‐3 PI3K 0.5 0.001026 80.99 2.022
PLX‐4720 918505‐84‐7 RAF Inactive 0.004833 115.72 2.523
Quercetin(Sophoretin) 117‐39‐5 PI3K | PKC Inactive 0.006617 92.57 1.533
R406 841290‐81‐1 Syk Inactive 0.003182 99.47 2.37
R406(free base) 841290‐80‐0 Syk Inactive 0.004251 102.03 1.87
RAF265 927880‐90‐8 RAF| VEGFR Inactive 0.003858 91.53 2.358
Rapamycin(Sirolimus) 53123‐88‐9 mTOR Inactive 0.002188 92.67 4.319
Roscovitine(CYC202) 186692‐46‐6 CDK Inactive 0.005643 98.59 4.712
SB 202190 152121‐30‐7 p38 MAPK Inactive 0.006036 111.95 2.016
SB 203580 152121‐47‐6 p38 MAPK 2.671028 0.00496 51.74 2.328
SB 216763 280744‐09‐4 GSK‐3 Inactive 0.005388 115.07 1.812
SB 431542 301836‐41‐9 ALK Inactive 0.005203 68.30 6.089
SB 525334 356559‐20‐1 ALK  Inactive NA 67.80 5
SGX‐523 1022150‐57‐7 c‐Met Inactive 0.005565 105.20 0.8619
SNS‐032(BMS‐387032) 345627‐80‐7 CDK Inactive 0.005256 91.11 3.691
SNS‐314 Mesylate 1057249‐41‐8 Aurora 0.709306 0.001203 28.64 3.885
Sorafenib Tosylate 475207‐59‐1 VEGFR | RAF | MEK 1.661538 0.001545 26.49 3.673
SP600125 129‐56‐6 JNK Inactive 0.009082 113.79 5.058
SU11274(PKI‐SU11274) 658084‐23‐2 c‐Met 0.5 0.000427 22.71 1.466
Sunitinib Malate 341031‐54‐7 FLT‐3 | VEGFR | Kit 0.819447 0.003755 57.09 1.194
Tandutinib (MLN518) 387867‐13‐2 FLT‐3 | c‐KIT Inactive NA 49.98 2.681
Temsirolimus 162635‐04‐3 mTOR 4 0.001941 104.51 2.349
TG100‐115 677297‐51‐7 PI3K Inactive 0.005775 106.47 1.064
TGX‐221 663619‐89‐4 PI3K Inactive 0.005488 109.95 3.552
TSU‐68 252916‐29‐3 VEGFR | FGFR Inactive 0.006444 97.45 5.416
U0126‐EtOH 1173097‐76‐1 MEK Inactive 0.004689 101.67 1.771
Vandetanib 443913‐73‐3 VEGFR | EGFR  0.922011 0.001273 26.65 4.188
Vatalanib 212141‐51‐0 VEGFR | c‐Kit | FLT‐3 Inactive NA 50.31 2.3
Vinorelbine(Navelbine) 71486‐22‐1 p38 MAPK 0.5 2.52E‐06 41.79 2.146
VX‐680 639089‐54‐6 Aurora 0.5 0.004305 62.61 2.246
VX‐702 479543‐46‐9 p38 MAPK Inactive 0.004947 96.01 4.057
VX‐745 209410‐46‐8 p38 MAPK Inactive 0.004584 85.93 4.995
WYE‐354 1062169‐56‐5 mTOR 0.5 0.004036 67.35 2.602
WZ3146 1214265‐56‐1 EGFR Inactive 0.004302 80.62 2.649
WZ4002 1213269‐23‐8 EGFR Inactive 0.004041 93.25 2.071
WZ8040 1214265‐57‐2 EGFR 1.58971 0.003539 46.43 1.866
XL147 956958‐53‐5 PI3K Inactive 0.004459 115.14 1.518
XL184 849217‐68‐1 c‐Met | FLT‐3 | VEGFR | c‐KIT Inactive 0.003988 102.47 2.262
XL765 1123889‐87‐1 PI3K Inactive 0.003335 113.85 2.006
XL880(GSK1363089) 849217‐64‐7 c‐Met | VEGFR 0.556082 0.00238 31.28 3.487
ZM‐447439 331771‐20‐1 Aurora 0.976484 1.55E‐05 81.73 3.426
ZSTK474 475110‐96‐4 PI3K Inactive 0.004791 106.50 2.439
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SUPPLEMENTAL MATERIAL 
Material and Methods 
 
Cell culture 
Human aortic endothelial cells (HAECs) from Cell Applications Inc (304-05a), were cultured 
in endothelial cell basal medium (LONZA Clonetics CC-3156 or ATCC PCS-100-030) with 
5% fetal bovine serum (GIBCO), 100U/mL of penicillin and 100µg/mL streptomycin (Sigma-
Aldrich), supplemented with singleQuots (LONZA Clonetics CC-4176 or ATCC PCS-100-
041, containing hFGF, hVEGF, hIGF-1, hEGF, hydrocortisone, ascorbic acid, heparin) 
hereafter referred to as medium A or singleQuots without VEGF, hereafter referred to as 
medium B at 37ºC in a humidified 5% CO2, 95% air incubator. According to the product 
description by ATCC, medium A contains 5 ng/ml VEGF-A. Lonza does not provide any 
public information on the VEGF-A content of its medium A. For some experiments (if 
indicated) we supplemented the VEGF-free medium B with 25 ng/ml VEGF-A (Sigma, 
V7259) 
 
  
Lipoprotein Isolation and labeling 
LDL (1.019<d<1.063 g/mL) and HDL (1.063<d<1.21 g/mL) were isolated from fresh human 
normolipidemic plasma of blood donors by sequential ultracentrifugation as described 
previously 1, 2. LDL and HDL were fluorescently labeled with Atto-488 (Atto-Tec, AD 488-35) 
and Atto-594-NHS-ester dyes, respectively (Atto-Tec, AD 594-35). The reaction was 
performed at a pH 8.0 adjusted by adding 1M NaHCO3 to obtain a final concentration of 0.1M 
in dark at room temperature for 1hour. The labeled lipoproteins were separated from free dye 
by gel filtration chromatography using PD-10 desalting columns (GE healthcare, 170851-01). 
LDL and HDL were radioiodinated with Na125I by the McFarlane monochloride procedure 
modified for lipoproteins 2, 3. Specific activities between 300-900 cpm/ ng of protein were 
obtained.  
 
Kinase inhibitor screen 
HAECs were seeded in 384 well plates (BD falcon, 353962) using a washer dispenser (Biotek, 
EL406), at a density of 1000 cells per well in medium A and cultured for 72 hours at 37ºC in a 
humidified 5% CO2, 95% air incubator. Following culture, cells were treated with a 141 drugs 
encompassing kinase inhibitor library (Selleckchem, L1200). For each drug, seven different 
concentrations were used at a dilution range of 128, 640, 3200, 16000, 80000, 400000, 
2000000. After 1 hour of drug treatment, cells were incubated with fluorescent labeled Atto594-
HDL and LDL [RFP (Red fluorescent protein) channel] for another hour. The cells were later 
washed with PBS using 384-well head manifold (Biotek, EL406), fixed with 2% 
paraformaldehyde and nuclei were stained with Hoechst- 33258 (Sigma, 861405). Nine 
images per well were acquired with 20x objective using widefield microscope (Molecular 
devices). The microscope generated images were processed by Cell profiler to segment nuclei 
and RFP foci intensity (HDL and LDL vesicles) per cell. Fitting of RFP foci per cell values as a 
function of drug-concentration was done in Genedata Screener (Genedata, Basel, 
Switzerland). The formula used to fit the dose-response data was a logistic function of the Hill 
Model type.   
                                             Y(X) = S∞ +       S0 - S∞ 
                                                                1 + (X/ IC50) nHill 
where X is the drug concentration, Y is the activity, S0 is fitted activity level at zero 
concentration (zero activity), S∞ is fitted activity level at infinite concentration (infinite activity), 
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nHill is the Hill coefficient for the curve which is the measure of the slope at IC50, IC50 is the 
concentration at which the uptake of fluorescent HDL  or LDL was inhibited by 50%. The fit 
parameters were constrained so that 0.5 ≤ nHill ≤ 4, S0 = 0, S∞ = -100. Prior to applying the 
Fisher exact test analysis, the drugs were classified as active based on the possibility to fit Hill 
model, and the rest of the drugs were assigned as inactive. The only arbitrary feature of this 
procedure is the choice to fit the logistic model only when the fluorescent signal drop was more 
than 50%. The reproducibility of the dose-response curves for foci per cell was assessed by 
the performance of two independent duplicate experiments. 
 
 
Small Interfering RNA Transfection 
Endothelial cells were reverse transfected with small interfering RNA (Ambion silencer select, 
Life technologies) targeted to VEGFR1 (s5287, s5288) or VEGFR2 (s7822, s7824) or VEGFR3 
(s5294, s5295) or AKT (s659, s660) or MAPK14 (p38 MAPK) (s3585, s3586) or MAP2K1 & 
MAPK2K2 (MEK1/2) (s11167, s11170) or SR-BI (s2648, s2649, s2650) or non-silencing 
control (4390843) at a final concentration of 5nmol/L using Lipofectamine RNA iMAX 
transfection reagent (Invitrogen, 13778150) in an antibiotic-free medium A or B as indicated.  
All experiments were performed 72 hours post-transfection and efficiency of transfection was 
confirmed with at least two siRNAs against each gene using quantitative RT-PCR and western 
blotting.  
 
Quantitative real time PCR 
Total RNA was isolated using TRI reagent (Sigma T9424) according to the manufacturer’s 
instruction. Genomic DNA was removed by digestion using DNase (Roche) and RNase 
inhibitor (Ribolock, Thermo Scientific).  Reverse transcription was performed using M-MLVRT 
(Invitrogen, 200U/µL) following the standard protocol as described by the manufacturer. 
Quantitative PCR was done with Lightcycler FastStart DNA Master SYBR Green I (Roche) 
using gene specific primers as followed:  
VEGFR1 (For: CTG AAG GAA GGG AGC TCG TC; Rev: GGC GTG GTG TGC TTA TTT GG),  
VEGFR2 (For: CGG TCA ACA AAG TCG GGA GA; Rev: CAG TGC ACC ACA AAG ACA CG),  
VEGFR3 (For: TCC TAC GTG TTC GTG AGA GAC; Rev: CAC CAG GAA GGG GTT GGA 
AA), 
SR-BI (For: CTG TGG GTG AGA TCA TGT GG; Rev: GCC AGA AGT CAA CCT TGC TC), 
normalized to GAPDH (For: CCC ATG TTC GTC ATG GGT GT; Rev: TGG TCA TGA GTC 
CTT CCA CGA TA). 
 
Wide-field Fluorescence Microscopy for coverslips 
Endothelial cells were cultured in medium A or medium B as monolayers on coverslips. After 
72hours, cells were subjected to treatment as indicated, followed by incubation with 50µg/mL 
of Atto594 labeled HDL or Atto488 labeled LDL for 1hour at 37 ºC as previously described 4. 
Cells were then washed, fixed with 2% paraformaldehyde and images were acquired on a 
Zeiss Axiovert 200M. 
 
MTT proliferation assay 
Endothelial cells were cultured in medium A or medium B at a density of 105 cells per well in a 
24 well plate. After 72 hours of culture, the supernatant was removed and cells were washed 
twice with PBS. The cells were then incubated with 30µL of MTT solution (5mg/ml in 
PBS,Sigma, M5655) diluted in 270µL of DMEM for 1 hour. The resultant formazan salts were 
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extracted with dimethyl sulfoxide (DMSO) and absorbance intensity was read at 550nm and 
reference wavelength at 650nm (DMSO). The rate of cell proliferation is calculated relative to 
the cells cultured in medium A. 
 
 
Lipoprotein Binding, Cell association and Transport 
The methods for the quantification of binding, association and transport of radiolabeled HDL 
and LDL by endothelial cells have been previously described 2, 5, 6. All assays were performed 
in DMEM (Sigma) containing 25mmol/L HEPES and 0.2% BSA instead of serum. Where 
indicated, cells were pretreated for 30mins at 37 ºC with PI3K inhibitor wortmannin (Sigma, 
200nmol/L) or Akt inhibitor MK2206 (Selleckchem, 1µmol/L) or Raf/MEK/ERK inhibitor U0126 
(Abcam, 10µmol/L) or p38MAPK inhibitor PD169316 (Calbiochem, 100nmol/L), followed by 
pre-treatment with VEGF-A165 (Sigma, 25ng/ml) for 1hr at 37 ºC. Following treatments, the 
cells were incubated with 10µg/mL of 125I-HDL/ LDL without (total) or with a 40 times excess 
of non-labeled HDL/ LDL (unspecific) for 1hr at 4 ºC for cellular binding and at 37ºC for 
association and transport experiments. Specific cellular binding/ association/ transport was 
calculated by subtracting the values obtained in the presence of excess unlabeled HDL/ LDL 
(unspecific) from those obtained in the absence of unlabeled HDL/ LDL (total). 
 
Western Blotting  
Endothelial cells were lysed in RIPA buffer (10mmol/L Tris pH 7.4, 150mmol/L NaCl, 1% NP-
40, 1% sodium deoxycholate, 0.1% SDS, complete EDTA (Roche)) with protease and 
phosphotase inhibitors. Equal amounts of protein were separated on SDS-PAGE and trans-
blotted onto PVDF membrane (GE Healthcare). Membranes were blocked in appropriate 
blocking buffer recommended for the antibody (TBS-T supplemented with 5% milk or BSA) 
and incubated either for 1hour or overnight on shaker at 4 ºC with primary antibodies at a 
dilution of 1:1000 in the same blocking buffer. Membranes were incubated for 1hour with HRP-
conjugated secondary antibody (Dako) in blocking buffer at a dilution of 1:2500. Membranes 
were further incubated with chemiluminescence substrate for 1min (Pierce ECL plus, Thermo 
scientific) and imaged using Fusion Fx (Vilber). As indicated Beta-Actin, GAPDH or TATA 
binding protein was used as loading control with primary antibody at 1:5000 and secondary 
antibody at 1:10000 dilutions. The silencing efficiencies of VEGFR1 (2893, CST), VEGFR2 
(9686, CST) and VEGFR3 (ab27278, Abcam) were evaluated and compared to Beta-Actin 
(ab8226, Abcam). The expression of SR-BI (NB400-131, Novus) was evaluated and compared 
to the expression of GAPDH (ab9484, Abcam). The silencing efficiencies of Akt (9272, CST), 
p38 MAPK (9212, CST) and MEK1/2 (8727, CST) were compared to TATA binding protein 
(TBP, ab51841, Abcam). The Phospho-expressions of VEGFR2 (3817, CST), Akt S473 (9271, 
CST), p38 MAPK Thr180/Tyr182 (9211, CST), p44/42 MAPK Thr202/Tyr204 & Thr185/Tyr187 
(9106, CST) were compared to the total expression of VEGFR2 (9698, CST), Akt (9272, CST), 
p38 MAPK (9212, CST) and p44/42 MAPK (4695, CST) respectively.  
 
Cell surface expression analysis  
Biotinylation of intact cells was performed using 20mg/mL EZ-Link sulfo-NHS-S-S-Biotin 
(Thermo Scientific) in the cold for 1 hour with mild shaking and quenched with ice-cold Tris pH 
7.4. Cells were lysed in RIPA buffer (total cell lysate) and 200-500µg of lysates were incubated 
with 20µL of BSA- blocked streptavidin beads suspension (GE Healthcare) for 16hours at 4 ºC 
and pelleted by centrifugation; the pellet represents surface proteins. Proteins were 
dissociated from the pellet by boiling with SDS loading buffer and analyzed by SDS-PAGE and 
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immunoblotting with SR-BI antibody (NB400-131, Novus) and LDL receptor (LDLR, ab30532, 
Abcam), ABCG1 (NB400-132, Novus). TATA binding protein (TBP, ab51841, Abcam) and 
endothelial lipase (EL,NB400-118, Novus) were used as intracellular and plasma membrane 
controls. 
 
 
Statistical Analysis 
Probability of finding active and inactive drugs for a given target compared to non-targeting 
drugs was performed using Fisher exact test analysis. The drugs were pre-classified as active 
based on their ability to fit the Hill logistic model only when the RFP foci signal dropped more 
than 50%. The data sets for all validation experiments were analyzed using the GraphPad 
Prism 5 software. Comparison between groups in follow up biochemical validation experiments 
was performed using Kruskal-Wallis one-way ANOVA followed by Dunn’s post test. The data 
was obtained from at least three independent experiments, performed in triplicates or 
quadruplets. Values are expressed as mean±SEM. P<0.05 was regarded as significant. 
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